You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Post-surgical Incision Management Device to Prevent Ostomy Complications

    SBC: FISTULA SOLUTION CORPORATION            Topic: 102

    Project Summary/Abstract Over 100,000 patients of all ages undergo ostomy surgery in the United States (US) annually due to a variety of pathophysiologic conditions including colorectal cancer, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), bowel obstruction, diverticulitis, and many other medical conditions. Ostomy surgery may also be necessary in cases of severe abdominal ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis

    SBC: HUMANETICS CORP            Topic: NHLBI

    Project Summary Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by progressive scarring of the tissue in the lungs. IPF is associated with a particularly poor prognosis with most patients succumbing to the disease within 3-5 years from the time of diagnosis. Two antifibrotic therapies, nintedanib and pirfenidone, have been approved in recent years for the treatment for ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines

    SBC: Vitakey Inc.            Topic: 300

    Project Summary/Abstract Enteral feeding (EF) is an essential medical procedure used to supply nutrients directly to the gastrointestinal (GI) tract of patients who are unable to eat independently. EF formula is often purchased as a ready-to-use liquid that contains carbohydrates, protein, fats, and micronutrients to ensure adequate nutritional benefit for the patient. The addition of therapeutic ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Stop pulmonary airleaks with a novel inhaled dry powder aerosol

    SBC: Quench Medical Inc.            Topic: NHLBI

    Project Summary AbstractOver 30,000 Americans suffer each year from pulmonary airleaks leading to collapsed lungs with painful, invasive treatments, and costly hospitalizations. Current treatments are not effective enough in controlling airleaks and medical providers are seeking new therapies. There is strong evidence that a locally delivered therapeutic via inhalation would have a major impact on ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A Vitamin K analog countermeasure for organophosphate poisoning

    SBC: NEUROENE THERAPEUTICS INC            Topic: NIAID

    Abstract Neuroene Therapeutics has discovered a novel class of well-tolerated, brain-penetrating, non-sedating compounds that are small analogs of Vitamin K (VK) that mimic the form of VK needed for mitochondrial and neurological health. Our VK analogs are effective in several animal models of pharmacoresistant seizures and Parkinson's disease. Our lead antiseizure drug (ASD) candidate is fast-act ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Technology Assisted Treatment for Binge Eating Behavior

    SBC: HABITAWARE, INC.            Topic: 104

    Abstract Significance: Binge-eating behavior is characterized by the consumption of a large amount of food and accompanied by the subjective experience of loss of control. Cognitive Behavioral Therapy has been shown to be effective, but CBT and other options for binge eating are limited because treatment is not effective in all patients, and because of high rates of relapse and attrition. A key re ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Hand Tremor Compensation Approach for Touch Screens

    SBC: Minnesota HealthSolutions Corporation            Topic: R

    Project Summary/Abstract The proposed project relates to the development of an innovative technological intervention to improve the usability of smartphones and other electronics devices for persons suffering from hand tremor. Given the ubiquitous presence of such electronics technology, our proposed intervention aims to significantly improve the quality of life of individuals afflicted with actio ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults

    SBC: MOAI TECHNOLOGIES, LLC            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) affects more than six million Americans currently and is projected to affect 14 million at a cost of $1.2 trillion in 2050. Despite its tremendous impacts and the limited influence of pharmacological therapies, attention has been brought to non-pharmacological interventions as promising therapeutic strategies for the prevention of cognitive decli ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. An automated system for post-surgical health and environmental monitoring with real-time alerts for laboratory rodents using scalable hardware and deep learning

    SBC: Applied Universal Dynamics, Corp.            Topic: OD

    Abstract This proposal responds directly to the PAR-21-225 Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models. While it is standard practice to continuously monitor the health of human patients following a major surgery, this is typically not the case for monitoring recovery in rodent pre- clinical research. For example, it is common practice that rats and ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government